FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Tysabri news from FiercePharma

News

Tysabri to get new Euro label

The European Medicines Agency called for an update to product information for Biogen Idec and Elan's multiple sclerosis drug Tysabri, highlighting the risk of a potentially deadly brain infection.... Read more...

Tysabri may deliver 'sustained improvement'

Tysabri may have scored a big plus for drugmakers Biogen Idec and Elan. A trial of the multiple sclerosis treatment showed that it might... Read more...

Biogen, Elan test Tysabri against cancer

Could Tysabri fight cancer as well as it battles multiple sclerosis? Biogen Idec and Elan aim to find out. The companies have given a multiple myeloma patient the first dose in the first clinical... Read more...

FDA, Biogen mull Tysabri label changes

The FDA is huddling with Biogen Idec and Elan on amendments to Tysabri's label. The reason, of course, is the Read more...

Icahn snaps up more of Biogen

The Biogen Idec faithful have been preaching "buying opportunity" ever since the company announced two new... Read more...

Judge strikes down Biogen preemption case

Biogen and Elan--along with proponents of preemption--were dealt a setback today as a federal judge declined to transfer a case from Massachusetts to a federal court in Iowa. The lawsuit stems from... Read more...

Analysts: Tysabri scrips will suffer

When Biogen Idec announced last week that a potentially fatal brain infection had cropped up again in Tysabri... Read more...

Biogen: Tysabri patients have PML

Biogen Idec CEO James Mullen predicted it, and now it's happened: Two Tysabri patients have come down with the potentially fatal brain infection, progressive multifocal leukoencephalopathy, or PML,... Read more...

Biogen CEO: Tysabri to reach $1B in 2008

Two years ago this week, Biogen Idec relaunched Tysabri, the multiple sclerosis and Crohn's disease treatment, after a safety scare. Now, the drug is shaping up to be a blockbuster, the Wall Street... Read more...

AZ, Amgen earnings flat; Shire sales leap

It's a mixed bag of drugmaker earnings reports today, with two biggies posting flat results and two smaller firms chalking up respectable gains.AstraZeneca's profits suffered under restructuring... Read more...

Press Releases

EU Panel Recommends Update For Elan, Biogen's Tysabri Label

EU Panel Recommends Update For Elan, Biogen's Tysabri Label ZURICH -(Dow Jones)- European Medicines Agency, an advisory body to the European drugs regulator, said Thursday it recommends an update of Read more >>

TYSABRI® DEMONSTRATES SUSTAINED IMPROVEMENT IN FUNCTIONAL OUTCOMES IN MULTIPLE SCLEROSIS PATIENTS ACCORDING TO NEW POST-HOC ANAL

TYSABRI® DEMONSTRATES SUSTAINED IMPROVEMENT IN FUNCTIONAL OUTCOMES IN MULTIPLE SCLEROSIS PATIENTS ACCORDING TO NEW POST-HOC ANALYSIS TYSABRI is the Only Marketed MS Treatment to Show Both Read more >>

First Multiple Myeloma Patient Treated

Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI® in Oncology First Multiple Myeloma Patient Treated CAMBRIDGE, Mass. & DUBLIN, Ireland--(BUSINESS WIRE)--Sept. 5, 2008--Elan Read more >>

FDA Updates the Information for Healthcare Professionals Sheet for Tysabri (natalizumab)

FDA Updates the Information for Healthcare Professionals Sheet for Tysabri (natalizumab) Information for Healthcare Professionals Natalizumab Injection for Intraveneous Use (marketed as Tysabri) Read more >>

Get more Tysabri coverage at: